Biocryst Pharmaceuticals (BCRX) Treasury Shares (2010 - 2026)

Biocryst Pharmaceuticals has reported Treasury Shares for 7 years, with the latest figure at $10.8 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares rose 19.09% year-over-year to $10.8 million; the trailing twelve-month figure through Mar 2026 stood at $10.8 million (up 19.09% YoY), and the FY2025 full-year result was $11.1 million, up 1253.71% from the prior year.
• Treasury Shares for Q1 2026 stood at $10.8 million, down from $11.1 million in the prior quarter.
• The five-year high for Treasury Shares was $11.1 million in Q4 2025, with the low at $588000.0 in Q4 2022.
• Historically, Treasury Shares has averaged $6.1 million across 5 years, with a median of $5.6 million in 2023.
• Annual changes were most pronounced in 2024 — Treasury Shares sank 85.28% — and 2025, when it soared 1253.71%.
• Biocryst Pharmaceuticals' Treasury Shares stood at $588000.0 in 2022, then jumped by 851.02% to $5.6 million in 2023, then slumped by 85.28% to $823000.0 in 2024, then soared by 1253.71% to $11.1 million in 2025, then fell by 2.8% to $10.8 million in 2026.
• The last three Treasury Shares figures came in at $10.8 million (Q1 2026), $11.1 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.